OncoMatch/Bile Duct Cancer (Cholangiocarcinoma)/IDH2
Bile Duct Cancer (Cholangiocarcinoma)IDH2 Clinical Trials
1 recruiting trials·Updated daily from ClinicalTrials.gov
IDH2 mutations occur in approximately 5% of cholangiocarcinoma, less frequently than IDH1, and produce 2-hydroxyglutarate through the same neomorphic mechanism. Enasidenib (an IDH2 inhibitor) and pan-IDH inhibitors covering both variants have been studied in biliary tract cancers. Trials evaluate selective IDH2 inhibitors and combination approaches in IDH2-mutant cholangiocarcinoma alongside IDH1-mutant cohorts.
Top recruiting
Top recruiting IDH2 Bile Duct Cancer (Cholangiocarcinoma) trials
Ranked by phase and US site count. See all 1 trials matched to your profile →
Other Bile Duct Cancer (Cholangiocarcinoma) biomarkers
Browse other molecular targets with active Bile Duct Cancer (Cholangiocarcinoma) trials.